Politico July 1, 2024
By Chelsea Cirruzzo and Ben Leonard

Driving the Day

HOW CHEVRON COULD SLOW THE FDA — A Friday Supreme Court ruling could mean it will take longer to develop new drugs and medical devices, former FDA attorneys say.

The Supreme Court overturned a Reagan-era precedent, called the Chevron deference, which required judges to defer to federal agencies’ interpretations of ambiguous federal laws.

The White House said the rule takes the country “backwards” and could “thwart efforts to respond to a global pandemic.”

The ruling could also mean new court challenges for the Biden administration’s Medicare drug negotiation policy and more pressure on Congress and the federal courts to hone their knowledge of health policy.

Slowed response time: The former FDA attorneys worry that the FDA’s process...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
GenAI and the revolution of drug development
Amgen starts two critical late-stage trials for weight loss drug MariTide
Patient Access To Cheaper Biosimilar Drugs Varies Significantly Across Pharmacy Benefit Managers
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
'Not just adding another drug to your pharmacy': CAR T, explained

Share This Article